Therapeutics– tag –
-
Oncology Drug Approval News Flash FDA approves nivolumab (Opdivo) with AVD chemotherapy for previously untreated advanced classical Hodgkin lymphoma (and converts prior accelerated approvals in relapsed/refractory cHL to traditional approval)
On March 20, 2026, the U.S. FDA approved nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and pediatric patients aged 12 years and older with previously untreated, Stage III or IV classica... -
Why Solid Tumors Are Hard for CAR-T: Reading the 3 Barriers That Define Today’s Clinical Bottleneck | Frontier of Therapy Series | CAR-T A3 [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) What yo... -
Current Standing of CAR-T Toxicity Management: 5 Implementation Challenges Across Site Ops, Long-Term Safety, and Regulation | Frontier of Therapy Series | CAR-T B2 [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A2: CAR-T side effects without panic (what happens, what to m Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + inde... -
How to Read CAR-T Side Effects: A 3-Axis Map of CRS, ICANS, and Cytopenia for Patients Without Panic | Frontier of Therapy Series | CAR-T A2 [Beginner]
New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index→ A1: Where CAR-T Is Used Tod New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Ther... -
FDA-Approved CAR-T Landscape: 7 Products and the Label Logic Behind Their Indications
Eleven CAR-T products have earned FDA approval, each targeting a specific cell, antigen, and disease. A single well-made table is worth a month of white papers—here is how to read it, and where the next approvals will land. Prefer the be... -
Where CAR-T Is Used Today: Reading the Indication Map Through 5 Blood Cancers and Today’s Standing | Frontier of Therapy Series | CAR-T A1 [Beginner]
New here? If you haven’t read the introduction, it will make this post much easier to follow.→ A0: What Is CAR-T Therapy? The Big Picture + Series Ind New here? If you haven’t read the introduction, it will make this post much easier to ... -
CAR-T at a Glance: A Beginner’s Map of Cells, Targets, and Why It Works
How to use this series (two-layer linkage: Beginner → Expert) This series explains CAR-T therapy in a stepwise way so that readers who are new to the term can first grasp the big picture (Layer A), and then move This series explains CAR-... -
Oncology Drug Approval News Flash FDA approves teclistamab (Tecvayli) plus daratumumab hyaluronidase-fihj for relapsed/refractory multiple myeloma (and converts Tecvayli monotherapy from accelerated to traditional approval)
On March 5, 2026, the U.S. FDA approved teclistamab (Tecvayli), a BCMA×CD3 bispecific antibody, in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least ... -
BRAF V600E CRC: What FDA’s Endorsement of Encorafenib + Cetuximab + Chemo Reshapes in 1L
FDA approval summary On February 24, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorourac... -
Cancer Worries Episode 3 — Metastasis: 4 Frames for Understanding How Cancer Spreads and What That Changes
“My stomach feels uncomfortable.” “I’ve had indigestion for weeks.” “My screening result says I need follow-up.” “I tested positive for H. pylori.” St “My stomach feels uncomfortable.” “I’ve had indigestion for weeks.” “My screening resu... -
Cancer Worries Episode 4 — Breast Cancer: 4 Subtype Pathways That Shape Today’s Personalized Treatment
“Is this a lump?” “Why does this side look different?” “There’s nipple discharge.” Breast cancer searches can quickly become overwhelming. “Is this a lump?” “Why does this side look different?” “There’s nipple discharge.” Breast cancer s... -
Cancer Worries Episode 2 — Colorectal Cancer: 5 Checkpoints That Reshape the Path from Screening to Treatment
“I noticed blood in my stool.” “My bowel habits have changed.” “My screening stool test came back positive.” Once you start searching, the amount of i “I noticed blood in my stool.” “My bowel habits have changed.” “My screening stool tes... -
Untangling Cancer Worries — Your First Guide, Part 8｜Lung Cancer Basics: A Calm One-Page Map of Tests, Staging, and Treatment in 3 Steps (With When-to-Seek-Care Signs)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstCommon entr... -
Cancer Worries Guide Part 7 — Breakthrough Treatments: Reading 5 Modalities Reshaping Modern Oncology
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstThe three t... -
Untangling Cancer Worries — Your First Guide, Part 6｜What Is a Rare Cancer? 3 Ways to Search When Information Is Limited (and What to Ask Clinicians)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat is a “... -
Optune Pax FDA承認: What Tumor Treating Fields Add to Locally Advanced Pancreatic Care
FDA approval summary On February 11, 2026, the U.S. Food and Drug Administration (FDA) approved a low electric field generator device, Optune Pax (Novocure), in combination with gemcitabine and nab-paclitaxel for the treatment of adult p... -
Untangling Cancer Worries — Your First Guide, Part 5｜Genetic Variants and Cancer Risk: 3 Things Tests Can Tell You (and What They Can’t)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat does “... -
Untangling Cancer Worries — Your First Guide, Part 4｜Benign vs Malignant Tumors: 3 Things to Confirm First Without Being Misled by the Words
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat does “... -
Untangling Cancer Worries — Your First Guide, Part 3｜What Does “Metastasis” Mean? 3 Differences From Stage and How Treatment Plans Can Change
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat is met... -
Platinum-Resistant Ovarian: Reading FDA’s Approval of Pembrolizumab + Paclitaxel ± Bevacizumab
FDA approval summary On February 10, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with...
